@spinogenix

spinogenix has been a member of Linktree for 2 years and joined in September 2023. The social media accounts linked to from spinogenix are: • Instagram • LinkedIn • X Besides social media accounts, spinogenix has populated their site with: • Spinogenix Announces FDA-Authorized Expanded Access Programfor SPG302, the First Synaptic Regenerative Therapy to Treat ALS - Spinogenix • Spinogenix Announces Open Enrollment for Phase 2 US Trial Following FDA Clearance of IND Application for SPG302, the First Synaptic Regenerative Therapy for Schizophrenia • Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity • Spinogenix's SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome • FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism - Spinogenix • Spinogenix Appoints American Football Hall of Famer and Health Advocate Steve Young to its Board of Directors - Spinogenix • Blog - Spinogenix • pharmashots.com • To Reverse Aging’s Clock, Adjust the Cell’s Machinery • Companies To Watch: Spinogenix • Spinogenix Announces Launch of Glaucoma Program and Addition of World-Renowned Expert Dr. Robert Weinreb to its Science Advisory Board - Spinogenix • Synapse-restoring pill set for human trials as novel schizophrenia treatment • First Synaptic Regenerative Therapy for Schizophrenia Under Investigation • Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia - Spinogenix • SPG601 for Restoring Synaptic Function in FXS • Channel 7 News Australia Feature • Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease - Spinogenix • Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X Syndrome - Spinogenix • What are the Current Investment Trends in the Pharmaceutical Industry, and How are They Influencing the Sector’s Direction? • Synapse-regenerating drug could reverse decline in Alzheimer’s - Drug Discovery World (DDW) • Courage and Connections: Dan Doctoroff and Stella Sarraf Discuss ALS, Synapses, and Spinogenix’s Innovative Approach - Spinogenix • FDA grants orphan designation to Fragile X syndrome therapeutic • Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome • MSN • The structure of an Amyloid Precursor Protein/talin complex indicates a mechanical basis of Alzheimer’s Disease • ClinicalTrials.gov • Channel 9 News Australia "A Promising New Drug" • SPG302 trial set to begin in Australia | MND Australia • Using EEG and TMS to capture treatment-related Brain Signals in Spinogenix Drug Trials • Actor Aaron Lazar opens up about ALS diagnosis • Investigating Auditory Electrophysiological Measures of Participants with Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Event-Related Potential Studies • onlinelibrary.wiley.com • Dysfunction of central control of breathing in amyotrophic lateral sclerosis - PubMed • SPG302 tested in a TAR4/4 ALS model by Dr. Justin Ichida at USC • 6th Annual ALS ONE Research Symposium: Day 2 Industry Speaker: Peter Vanderklish, PhD of Spinogenix. • SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer’s Disease - Neurotherapeutics • An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD - Acta Neuropathologica • Integrative proteomics highlight presynaptic alterations and c-Jun misactivation as convergent pathomechanisms in ALS - Acta Neuropathologica • Spinogenix Awarded Department of Defense Grant • Spinogenix Website • Spinogenix Awarded $3 Million NIH Alzheimer's Grant